Kane Biotech (TSE:KNE) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kane Biotech has announced that BioStem Technologies will acquire exclusive U.S. distribution rights for its revyve Antimicrobial Wound Gel from ProgenaCare Global, marking a strategic move to enhance BioStem’s wound care portfolio. This acquisition is expected to significantly boost the market presence of revyve products in the U.S., leveraging BioStem’s strong growth and commercial infrastructure in the sector.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.